{"id":"placebo-rituximab","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion-related reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their destruction through mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This results in a reduction in B cell count and activity, which can be beneficial in treating certain autoimmune and malignant conditions.","oneSentence":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:46.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT03844061","phase":"PHASE2","title":"Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-07-29","conditions":"Systemic Sclerosis","enrollment":30},{"nctId":"NCT06388941","phase":"PHASE2","title":"Iptacopan in Patients With ANCA Associated Vasculitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-08-05","conditions":"Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis","enrollment":84},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT06599307","phase":"PHASE2","title":"The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-08-01","conditions":"Secondary Progressive Multiple Sclerosis (SPMS)","enrollment":46},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT07157787","phase":"PHASE2","title":"Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-09-19","conditions":"Primary Membranous Nephropathy","enrollment":30},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":"Lymphoma, Mantle Cell","enrollment":635},{"nctId":"NCT03295383","phase":"PHASE3","title":"Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2019-07-11","conditions":"Severe Forms of Mucous Membrane Pemphigoid","enrollment":130},{"nctId":"NCT07409428","phase":"PHASE3","title":"A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Hutchmed","startDate":"2026-03-10","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":240},{"nctId":"NCT03949855","phase":"PHASE2","title":"Belimumab With Rituximab for Primary Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-03-06","conditions":"Membranous Nephropathy, Nephrotic Syndrome","enrollment":58},{"nctId":"NCT06356129","phase":"PHASE3","title":"Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-06-19","conditions":"Large B-cell Lymphoma","enrollment":850},{"nctId":"NCT03274492","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-11-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1000},{"nctId":"NCT05533164","phase":"PHASE3","title":"Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sint Maartenskliniek","startDate":"2023-02-09","conditions":"Polymyalgia Rheumatica","enrollment":174},{"nctId":"NCT05533125","phase":"PHASE3","title":"Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed","status":"COMPLETED","sponsor":"Sint Maartenskliniek","startDate":"2023-02-01","conditions":"Polymyalgia Rheumatica","enrollment":114},{"nctId":"NCT06688331","phase":"PHASE2","title":"Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody","status":"RECRUITING","sponsor":"PolTREG S.A.","startDate":"2025-03-12","conditions":"Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1","enrollment":150},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT02990286","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2017-01-20","conditions":"Lung Disease, Interstitial","enrollment":122},{"nctId":"NCT04529772","phase":"PHASE3","title":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2020-10-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":611},{"nctId":"NCT04680052","phase":"PHASE3","title":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-04-15","conditions":"Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":654},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT05136976","phase":"PHASE3","title":"Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-06-29","conditions":"Anti-MAG Neuropathy","enrollment":90},{"nctId":"NCT02433522","phase":"PHASE3","title":"Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-31","conditions":"ANCA-associated Vasculitides","enrollment":97},{"nctId":"NCT06047171","phase":"PHASE2","title":"Rescue of Nephrons With ALE.F02 (RENAL-F02)","status":"RECRUITING","sponsor":"Alentis Therapeutics AG","startDate":"2023-09-07","conditions":"Glomerulonephritis Rapidly Progressive","enrollment":80},{"nctId":"NCT06186219","phase":"PHASE1","title":"Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2024-04-10","conditions":"Tophaceous Gout","enrollment":2},{"nctId":"NCT03164473","phase":"PHASE3","title":"Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-03-07","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":98},{"nctId":"NCT01748084","phase":"PHASE2, PHASE3","title":"Rituximab in Systemic Sclerosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-04-09","conditions":"Systemic Sclerosis","enrollment":22},{"nctId":"NCT07038382","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-08-05","conditions":"Membranous Nephropathy, Lupus Nephritis (LN)","enrollment":24},{"nctId":"NCT02367040","phase":"PHASE3","title":"Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-08-03","conditions":"Lymphoma,Non-Hodgkin","enrollment":458},{"nctId":"NCT04442022","phase":"PHASE2, PHASE3","title":"A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-09-03","conditions":"Relapsed/Refractory Diffuse Large B-cell Lymphoma","enrollment":501},{"nctId":"NCT03290456","phase":"NA","title":"Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2019-08-20","conditions":"Granulomatosis With Polyangitis","enrollment":146},{"nctId":"NCT03763643","phase":"EARLY_PHASE1","title":"PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2019-07-01","conditions":"Focal Segmental Glomerulosclerosis","enrollment":21},{"nctId":"NCT04824092","phase":"PHASE3","title":"Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2021-05-11","conditions":"Diffuse Large B-cell Lymphoma","enrollment":899},{"nctId":"NCT05868837","phase":"PHASE3","title":"Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-02-28","conditions":"Myasthenia Gravis, Generalized","enrollment":40},{"nctId":"NCT04212013","phase":"PHASE3","title":"A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-23","conditions":"Marginal Zone Lymphoma","enrollment":23},{"nctId":"NCT01776840","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-05-16","conditions":"Mantle Cell Lymphoma","enrollment":523},{"nctId":"NCT05211401","phase":"PHASE2","title":"Rituximab in Patients With ST-elevation Myocardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-06-01","conditions":"ST Elevated Myocardial Infarction","enrollment":372},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT06601504","phase":"PHASE2","title":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hutchmed","startDate":"2024-11-05","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":61},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT06952413","phase":"PHASE2","title":"Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)","status":"RECRUITING","sponsor":"National Center of Neurology and Psychiatry, Japan","startDate":"2025-04-09","conditions":"Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)","enrollment":30},{"nctId":"NCT03194815","phase":"PHASE2","title":"IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","status":"RECRUITING","sponsor":"University of Cambridge","startDate":"2017-11-01","conditions":"Psychosis, Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT01363388","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-09","conditions":"Vasculitis","enrollment":67},{"nctId":"NCT05329090","phase":"PHASE3","title":"Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hopital Foch","startDate":"2022-03-11","conditions":"IgA Vasculitis","enrollment":75},{"nctId":"NCT02222155","phase":"PHASE2","title":"Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-04","conditions":"ANCA-associated Vasculitis","enrollment":42},{"nctId":"NCT06226662","phase":"PHASE2","title":"Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":12},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT05914155","phase":"PHASE3","title":"Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome","status":"RECRUITING","sponsor":"Shoichi Maruyama MD PhD","startDate":"2023-06-24","conditions":"Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic","enrollment":88},{"nctId":"NCT00740948","phase":"PHASE2, PHASE3","title":"Tolerance and Efficacy of Rituximab in Sjogren's Disease","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2008-03","conditions":"Sjogren's Disease","enrollment":122},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT06363994","phase":"PHASE3","title":"A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL","status":"RECRUITING","sponsor":"InnoCare Pharma Inc.","startDate":"2024-05-29","conditions":"Mantle Cell Lymphoma","enrollment":476},{"nctId":"NCT05622201","phase":"PHASE2","title":"A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2023-03-21","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":120},{"nctId":"NCT02626455","phase":"PHASE3","title":"Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)","status":"TERMINATED","sponsor":"Bayer","startDate":"2016-01-06","conditions":"Lymphoma, Non-Hodgkin","enrollment":551},{"nctId":"NCT04231448","phase":"PHASE3","title":"Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2020-05-21","conditions":"Diffuse Large B-cell Lymphoma","enrollment":423},{"nctId":"NCT04323566","phase":"PHASE2","title":"Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement","status":"ENROLLING_BY_INVITATION","sponsor":"Uppsala University Hospital","startDate":"2022-05-01","conditions":"Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia","enrollment":40},{"nctId":"NCT04480307","phase":"PHASE2","title":"Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","sponsor":"GeNeuro Innovation SAS","startDate":"2020-06-17","conditions":"Multiple Sclerosis","enrollment":41},{"nctId":"NCT02950155","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis","status":"COMPLETED","sponsor":"Fredrik Piehl","startDate":"2016-10-16","conditions":"Generalized Myasthenia Gravis","enrollment":47},{"nctId":"NCT03078855","phase":"PHASE3","title":"A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Jonathan Friedberg","startDate":"2017-09-07","conditions":"Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma","enrollment":211},{"nctId":"NCT01969409","phase":"PHASE2","title":"Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2014-01","conditions":"Ambulatory IPF","enrollment":58},{"nctId":"NCT06549231","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Tours","startDate":"2024-11-15","conditions":"Interstitial Lung Disease With Systemic Sclerosis","enrollment":102},{"nctId":"NCT05596786","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial","status":"RECRUITING","sponsor":"University Hospital, Tours","startDate":"2023-01-16","conditions":"Lung Diseases","enrollment":126},{"nctId":"NCT03010202","phase":"PHASE3","title":"The PROLONG Trial - Rituximab Maintenance Therapy in ITP","status":"UNKNOWN","sponsor":"Ostfold Hospital Trust","startDate":"2016-12","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":136},{"nctId":"NCT06325943","phase":"PHASE3","title":"Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy","status":"COMPLETED","sponsor":"Istituto Clinico Humanitas","startDate":"2019-04-01","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":37},{"nctId":"NCT02451111","phase":"PHASE2","title":"Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2015-11-06","conditions":"Follicular Lymphoma","enrollment":190},{"nctId":"NCT05234684","phase":"PHASE3","title":"A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2022-11-02","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":150},{"nctId":"NCT02369016","phase":"PHASE3","title":"Phase III Copanlisib in Rituximab-refractory iNHL","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-22","conditions":"Lymphoma, Non-Hodgkin","enrollment":25},{"nctId":"NCT02204982","phase":"PHASE3","title":"Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma","status":"TERMINATED","sponsor":"SecuraBio","startDate":"2014-09","conditions":"Follicular Lymphoma","enrollment":13},{"nctId":"NCT05338190","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-14","conditions":"Primary Immune Thrombocytopenia (ITP)","enrollment":132},{"nctId":"NCT05962840","phase":"PHASE4","title":"Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2023-06-29","conditions":"ANCA Associated Vasculitis","enrollment":40},{"nctId":"NCT02285062","phase":"PHASE3","title":"Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-02-17","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":570},{"nctId":"NCT04236141","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-10","conditions":"Diffuse, Large B-Cell, Lymphoma","enrollment":42},{"nctId":"NCT01938001","phase":"PHASE3","title":"Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-11-21","conditions":"Lymphoma, Non-Hodgkin","enrollment":358},{"nctId":"NCT01086540","phase":"PHASE2","title":"Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-06-24","conditions":"Systemic Sclerosis-Associated PAH","enrollment":57},{"nctId":"NCT04880577","phase":"PHASE2","title":"Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-09-15","conditions":"Multiple Sclerosis, Relapsing-Remitting, Fatigue","enrollment":""},{"nctId":"NCT03920722","phase":"PHASE3","title":"Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-24","conditions":"Microscopic Polyangiitis (MPA)","enrollment":8},{"nctId":"NCT04796922","phase":"PHASE3","title":"To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2022-12-30","conditions":"Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)","enrollment":""},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT04849715","phase":"PHASE3","title":"A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2022-03-11","conditions":"Mantle Cell Lymphoma","enrollment":""},{"nctId":"NCT03967925","phase":"PHASE2","title":"Rituximab and Belimumab Combination Therapy in PR3 Vasculitis","status":"UNKNOWN","sponsor":"Rachel Jones","startDate":"2019-02-01","conditions":"ANCA Associated Vasculitis, Granulomatosis With Polyangiitis","enrollment":31},{"nctId":"NCT01556776","phase":"PHASE3","title":"A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2012-07-20","conditions":"Chronic Lymphocytic Leukemia","enrollment":89},{"nctId":"NCT02266888","phase":"PHASE2","title":"B Cell Induction in Pediatric Lung Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-01-22","conditions":"Lung Transplant","enrollment":45},{"nctId":"NCT02746744","phase":"PHASE3","title":"RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.","status":"COMPLETED","sponsor":"Anders Svenningsson","startDate":"2016-05","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":200},{"nctId":"NCT00299182","phase":"PHASE1, PHASE2","title":"Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-03","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT03864185","phase":"PHASE2","title":"The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies","status":"COMPLETED","sponsor":"Nagoya University","startDate":"2019-03-28","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","enrollment":25},{"nctId":"NCT02631538","phase":"PHASE2","title":"Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02-17","conditions":"Sjogren's Syndrome","enrollment":86},{"nctId":"NCT00848692","phase":"PHASE2, PHASE3","title":"Drug Intervention in Chronic Fatigue Syndrome","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2008-06","conditions":"Chronic Fatigue Syndrome","enrollment":30},{"nctId":"NCT02229942","phase":"PHASE3","title":"B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2014-09","conditions":"Chronic Fatigue Syndrome/ Myalgic Encephalitis (CFS/ME)","enrollment":151},{"nctId":"NCT02576275","phase":"PHASE3","title":"A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)","status":"WITHDRAWN","sponsor":"SecuraBio","startDate":"2015-12","conditions":"Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma","enrollment":""},{"nctId":"NCT02165397","phase":"PHASE3","title":"Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2014-07-07","conditions":"Waldenström's Macroglobulinemia","enrollment":181},{"nctId":"NCT04531865","phase":"PHASE3","title":"Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2021-01-01","conditions":"Frequently Relapsing Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome","enrollment":""},{"nctId":"NCT02383589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-26","conditions":"Pemphigus Vulgaris","enrollment":135},{"nctId":"NCT01278745","phase":"PHASE2","title":"Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Cardiac Allograft Vasculopathy, Heart Transplant Recipients","enrollment":362},{"nctId":"NCT02394106","phase":"PHASE2","title":"Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome","status":"TERMINATED","sponsor":"Istituto Giannina Gaslini","startDate":"2015-07","conditions":"Nephrotic Syndrome","enrollment":13},{"nctId":"NCT00279305","phase":"PHASE2","title":"Rituximab in New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2005-08","conditions":"Type 1 Diabetes Mellitus","enrollment":87},{"nctId":"NCT02789397","phase":"PHASE2","title":"Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency","status":"WITHDRAWN","sponsor":"Medical College of Wisconsin","startDate":"2016-05-02","conditions":"Granulomatous and Lymphocytic Interstitial Lung Disease","enrollment":""},{"nctId":"NCT01569295","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-06-15","conditions":"Chronic Lymphocytic Leukemia","enrollment":416}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["nacl"],"phase":"phase_3","status":"active","brandName":"Placebo-rituximab","genericName":"Placebo-rituximab","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}